Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Gross Margin: 2021-2025

Historic Gross Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to 88.80%.

  • Kiniksa Pharmaceuticals International's Gross Margin rose 672.00% to 88.80% in Q3 2025 from the same period last year, while for Sep 2025 it was 87.52%, marking a year-over-year increase of 121.00%. This contributed to the annual value of 85.61% for FY2024, which is 203.00% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Gross Margin stood at 88.80% for Q3 2025, which was up 0.75% from 88.14% recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Gross Margin peaked at 104.52% during Q4 2022, and registered a low of 77.12% during Q3 2021.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Gross Margin averaged around 88.18%, with its median value being 88.14% (2025).
  • Its Gross Margin has fluctuated over the past 5 years, first spiked by 2,515bps in 2022, then tumbled by 1,602bps in 2023.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Gross Margin stood at 79.37% in 2021, then spiked by 2,515bps to 104.52% in 2022, then plummeted by 1,602bps to 88.51% in 2023, then slumped by 311bps to 85.40% in 2024, then spiked by 672bps to 88.80% in 2025.
  • Its last three reported values are 88.80% in Q3 2025, 88.14% for Q2 2025, and 87.03% during Q1 2025.